U.S., Feb. 25 -- ClinicalTrials.gov registry received information related to the study (NCT06842498) titled 'A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)' on Feb. 19.
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior second-generation androgen receptor signaling inhibitor (ARSI) in any setting and no prior taxane therapy in the mCRPC setting.
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-Resistant Prostate Cancer
Intervention: ...